There are currently 1113 ongoing clinical trials involving Small-Cell Lung Cancer
Of the 1113 trials,288 trials are in Phase II
Furthermore, 281 trials are in Phase I/II
The global pharmaceutical industry is steadily developing new drugs for Small-Cell Lung Cancer, an Oncology condition. The largest number of ongoing clinical trials for Small-Cell Lung Cancer is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Small-Cell Lung Cancer-related drug trials.
National Cancer Institute US: The leading ongoing Small-Cell Lung Cancer related clinical trial sponsor
National Cancer Institute US is the top sponsor for Small-Cell Lung Cancer-related ongoing clinical trials.
F.Hoffmann-La Roche Ltd, AstraZeneca Plc, Jiangsu Hengrui Medicine Co Ltd, Shanghai Pulmonary Hospital, and Merck & Co Inc are among other notable clinical trial sponsors involved in Small-Cell Lung Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Small-Cell Lung Cancer
Pembrolizumab (Keytruda), Nivolumab (Opdivo, Opdyta), and Atezolizumab (Tecentriq) are key marketed drugs involving Small-Cell Lung Cancer.
Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Keytruda is formulated as a lyophilized powder for solution, solution concentrate for intravenous route of administration. Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Pembrolizumab was first approved in 2014 and is marketed globally including in the US, the UK, Australia, France, Germany, China, and Japan by Merck Sharp & Dohme Corp.
Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal antibody. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Opdivo is formulated as a solution and concentrate solution for intravenous route of administration. Nivolumab is indicated for the treatment of unresectable melanoma. Opdivo as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation was positive, a BRAF inhibitor. Nivolumab was first approved in 2014 and is marketed globally including in the US, the UK, Australia, France, Germany, China, and Japan by Bristol-Myers Squibb Co.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward